Full Press Release Details
At SL Science, we believe that real progress in cell therapy comes from asking hard questions before the easy answers arrive. That's the spirit behind our latest publication, co-authored by our leadership team alongside clinical researchers from Taipei Medical University, now published in the peer-reviewed journal Biomedicines.
Our paper takes on one of oncology's most stubborn challenges: glioblastoma, the most common and aggressive primary brain cancer in adults. Despite decades of research, treatment outcomes have changed little. We wanted to understand why — and what it would actually take for a new class of therapy to succeed where others have failed.
Why We Believe γδ T Cells Deserve Attention
Glioblastoma is notoriously difficult to treat because tumors mutate quickly, slipping past therapies built to hit a single target. γδ T cells work differently. Rather than relying on one specific antigen, they recognize cancer through broad stress signals — a mechanism that may make them harder for the tumor to outmaneuver. They also show the ability to target the stem-like cells believed to drive recurrence, and they carry a lower risk of graft-versus-host disease than some other cell types.
This biology aligns closely with the platform we've been building: one designed for allogeneic, "off-the-shelf" manufacturing from healthy donors, and for repeated, localized delivery directly to the brain.
What We Think Needs to Change
Publishing this framework alongside clinical researchers wasn't just about presenting an opportunity — it was about being honest regarding what still needs to be proven. Our paper lays out specific operational shifts we believe future trials must adopt:
• Early-phase trials need to embed quantitative cell-tracking and serial pharmacodynamic sampling, so we can tell whether an outcome is driven by delivery, persistence, or functional exhaustion of the cells.
• Potency testing should happen under realistic tumor conditions — low oxygen, low glucose — not just in ideal laboratory environments.
• Direct, repeated delivery to the tumor cavity remains, in our view, the most practical way to work around the blood-brain barrier.
• Trial endpoints should prioritize verifiable biological activity before attempting to prove survival benefit in small, early-stage cohorts.
Early-phase trials need to embed quantitative cell-tracking and serial pharmacodynamic sampling, so we can tell whether an outcome is driven by delivery, persistence, or functional exhaustion of the cells.
Potency testing should happen under realistic tumor conditions — low oxygen, low glucose — not just in ideal laboratory environments.
Direct, repeated delivery to the tumor cavity remains, in our view, the most practical way to work around the blood-brain barrier.
Trial endpoints should prioritize verifiable biological activity before attempting to prove survival benefit in small, early-stage cohorts.
In Our Chairman's Words
"Glioblastoma has repeatedly defeated therapies that looked convincing in preclinical models," said William Wang, our Chairman and Chief Executive Officer. "The clear lesson is that progress depends on rigorous evidence generation in humans, not further laboratory speculation. This publication defines what we believe the next phase of development must look like — trials designed from day one to show whether these cells reach the tumor, remain viable, and execute their therapeutic function. We intend our own programs to meet the exact standard we've set out here."
Where the Science Stands Today
We want to be clear-eyed about where this field currently stands. γδ T cell therapy in glioblastoma remains investigational. This publication is an independent narrative review, written by our leadership in their personal scientific capacity — it received no external funding, was conducted independently of any commercial product, and does not evaluate or endorse any specific SL Science candidate.
We're sharing this work because we believe the standard it sets is one our own programs should be held to. Read the full peer-reviewed article here: https://doi.org/10.3390/biomedicines14081770
Contact Details
SL Science Holding Limited
Tel: +886-2-26516826
Email: ir@slbtgroup.com
WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214